GLP-1 medications like Ozempic and Wegovy have transformed weight loss for millions, but a significant minority experience little to no benefit despite taking the drugs exactly as prescribed. Between 9% and a third of clinical trial participants lose less than 5% of their body weight, depending on the drug and dose used. For these non-responders, the disappointment runs deep, especially after investing time, money, and hope in a treatment that promised transformation.

Why Don't GLP-1 Drugs Work for Everyone?

The short answer is that researchers are still piecing together the puzzle. "The short answer to why some people don't respond is we don't really know," explained Prof Alexander Miras, an obesity expert at Ulster University. However, emerging research has identified several factors that appear to influence how well these medications work, ranging from genetics to eating behavior patterns.

One of the most striking discoveries comes from 23andMe Research Institute researchers, who found that genetic variants affecting brain receptors where GLP-1 drugs work play a measurable role. "People carrying the genetic variant, we found lose about an extra 0.76kg (1.6 lbs) on average, and people who carry two copies of the variant double that," said Adam Auton, vice-president of human genetics at 23andMe Research Institute. For people with two copies of the variant, this accounts for roughly 10% of the weight they might expect to lose on these medications.

Other research has identified genetic variants affecting an enzyme called PAM, which modifies GLP-1 and other hormones. People carrying these variants appear to show resistance to GLP-1, meaning the medication has less effect on their bodies.

What Personal Characteristics Predict Weight Loss Success?

Beyond genetics, several ordinary clinical traits do surprisingly strong predictive work. Gender emerges as the strongest demographic predictor: women, on average, lose more weight on GLP-1 drugs than men. Age also plays a role, with older people tending to lose less weight than younger individuals.

People with type 2 diabetes present an interesting pattern. While they do lose weight on GLP-1 medications, they typically shed somewhat less than people without diabetes. Additionally, hormonal factors appear to matter. Research suggests that estrogen alters GLP-1 response, which may explain differences between male and female weight loss, and even variations based on the menstrual cycle.

How a person overeats may also predict medication success. Research from Japan found that people who overeat because food looks and smells appealing tend to lose more weight, while those who eat emotionally in response to stress or mood tend to see weaker results. However, emotional eating is not a reason to avoid these drugs. "Emotional eating is not a contraindication to GLP-1 receptor agonist use, but rather a signal that more help may be needed," noted Dr. Anthony Puopolo, chief medical officer at LifeMD.

Dr. Anthony Puopolo, chief medical officer at LifeMD

How to Identify Your Likelihood of Success Before Starting

• Early Weight Loss Response: The strongest signal available is how much weight you lose in the first three months. A drop of at least 5 pounds in the first three months outperforms any known genetic marker in predicting long-term success.
• Eating Behavior Assessment: Simple questionnaires like the Dutch Eating Behavior Questionnaire or the Emotional Eating Questionnaire can be administered in minutes to identify whether you're an external, emotional, or restrained eater, helping doctors tailor additional support.
• Medical History Review: Discuss with your doctor whether you have type 2 diabetes, your age, and any hormonal factors like menopause or hormone replacement therapy use, as these influence medication effectiveness.
• Genetic Testing Limitations: While genetic variants have been identified, a clinically useful pre-treatment genetic test to predict GLP-1 drug response is not yet close to clinical readiness, despite genuinely important recent discoveries.

Dr. Puopolo clarified that measuring baseline endogenous GLP-1 levels, a natural hormone your pancreas produces, is not currently useful for predicting who will respond to semaglutide or tirzepatide. Similarly, there is no evidence supporting pre-treatment microbiome optimization before starting these drugs, despite popular theories about gut health.

What Happens to Non-Responders?

For people like Mercedes, a recently retired teacher in her 50s from Canada, non-response has been emotionally devastating. She tried Ozempic for nine months, then Wegovy for four months, followed by Contrave, Mounjaro, and finally Zepbound over nine months. "Nothing has worked," she said. Despite strict adherence to lifestyle changes, she experienced constant, intrusive thoughts about food. "The cravings, which I can only call like heroin withdrawal, it's just overwhelming," she described.

Yury K, 57, from Canada, had a similar experience. He exercises about five days a week with kettlebells and avoids junk food, yet after six months on Wegovy, his weight remained essentially unchanged at around 242 pounds. He also experienced unpleasant side effects including constipation and sensitive skin. "When you put in the effort with diet and exercise, take the medication exactly as prescribed, and still see little benefit, it is difficult not to feel disappointed," he said.

For some, the issue isn't initial non-response but loss of effectiveness over time. Lucille, 53, from Luxembourg, initially saw results on GLP-1 medications but found they no longer helped her lose weight, even after switching to Mounjaro at the highest dose.

What Should You Ask Your Doctor Before Starting?

The most important question patients forget to ask is one that catches many off guard: "What happens if I stop?". The honest answer surprises most people. Studies show that most people regain much of the weight they lost after stopping a GLP-1 medication, with blood sugar, blood pressure, and cholesterol levels drifting back up as well. In the STEP 1 trial extension, participants regained roughly two-thirds of their lost weight in the year after stopping semaglutide.

"GLP-1 medicines are often seen as a long-term treatment for chronic diseases, so it's worth asking yourself honestly whether you're ready for that commitment, paired with sustainable lifestyle changes," explained Dr. Oluwatosin Ajao, an obesity medicine physician known to her patients as Dr. Tosin.

Dr. Oluwatosin Ajao, Obesity Medicine Physician

Before starting, Dr. Tosin also recommends discussing medical appropriateness. "The first question to ask is the medical appropriateness of a GLP-1 medicine for you," she stated. These medications are designed for adults with obesity (a BMI of 30 or higher, roughly 207 pounds for someone 5'10") or who are overweight (BMI 27 or higher) and have a weight-related health problem such as high blood pressure, type 2 diabetes, or high cholesterol.

Dr. Tosin also

You should also disclose your full medical history, including any history of pancreatitis, slow stomach emptying, past bariatric or stomach surgery, diabetic eye disease, or gallbladder problems. Certain conditions make these drugs unsafe: a personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia type 2 (MEN2), severe kidney disease, or pregnancy.

The reality is that GLP-1 medications represent a genuine breakthrough for many, but they are not a universal solution. Understanding the factors that predict success, asking the right questions upfront, and having realistic expectations about long-term commitment can help patients and doctors make informed decisions about whether these drugs are the right choice.